Upgrade to SI Premium - Free Trial

Entera Bio shares Phase 2 EB613 bone density data at ASBMR meeting

October 13, 2026 7:01 AM
Entera Bio Ltd. (NASDAQ: ENTX) presented post-hoc Phase 2 data and a Phase 3 study design for its oral osteoporosis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA